0

Close
 
Upcoming Allied Market Research
2023
Uterine Fibroid Embolization Agents Market

Uterine Fibroid Embolization Agents Market

by Type (Gelatin Sponge, Polyvinyl Alcohol (PVA) Particles, Trisacryl Gelatin Microspheres (TAGM), Polymethyl Methacrylate (PMMA) Microspheres): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Healthcare
Report Code: A01186
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Uterine Fibroid Embolization Agents Market

Request Now !

Uterine fibroid embolization (UFE) is an effective, non-surgical method used to treat uterine fibroids in the fertile women population. It is performed with the help of uterine fibroid embolization agents, delivered to the tumor by micro-catheters. Uterine fibroids are benign growths in the uterus that can be asymptomatic and seen during the fertile period. Depending on the size and location of the fibroid in uterus, it can cause pain and heavy bleeding during menstrual cycle and affect the ability of a woman to conceive. The embolization agents block the arteries supplying blood to the tumor and force them to shrink. It is the most common form of tumor found in female reproductive system and therefore it is now one of the rising concerns amongst women. The increased awareness about the uterine fibroids amongst women and popularity of minimally invasive procedure will drive the global market for uterine fibroid embolization agents. In addition, the fact that UFE allows woman to preserve their uterus, otherwise not possible with full or even partial hysterectomy will further drive the market. Even though UFE is emerging as one of the most effective treatment available for UFE, side-effects such as infections, premature menopause, inflammation, and loss of menstrual periods can act as a barrier in the growth of the uterine fibroid embolization agents market.

Top uterine fibroid embolization agents considered in this report are gelatin sponge, polyvinyl alcohol (PVA) particles, trisacryl gelatin microspheres (TAGM), and polymethyl methacrylate (PMMA) microspheres. PMMA microspheres received its FDA approval in 2014 for the use in the treatment of uterine fibroids and as they are more spherical and biocompatible in nature, they are expected to acquire the major share of the uterine fibroid embolization agents market in the future. Geographically, the report is segmented into four regions namely North America, Europe, Asia-Pacific, and LAMEA. The major players for uterine fibroid embolization agents are Astellas Pharma, Nippon Kayaku, Pfizer, Boston Scientific Corporation, Merit Medical Systems, Inc. and Cook Medical. As few companies are present in the market, acquisitions and collaborations were seen in the past. In November 2015, Boston Scientific Corporation acquired the interventional radiology segment of the CeloNova Biosciences (sole manufacturer of the PMMA microspheres in the world) to establish itself as the strongest player in the interventional oncology business.

KEY MARKET BENEFITS:

  • This report provides an extensive analysis of the current and emerging trends in the world uterine fibroid embolization agents market.
  • The market projections will be present in the report along with factors affecting the same.
  • In-depth analysis of the market by geography would give an idea about the government regulations, which in turn would help in understanding the regional market.
  • In-depth analysis of the market based on type would give a clear idea about the trending products to identify the market opportunities and plan product developments.
  • The report also provides comprehensive analysis of drivers and constraints of the uterine fibroid embolization agents market.
  • The key players are profiled in the report, and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
  • Competitive intelligence highlights the business practices followed by leading market players across geographies.

 Uterine Fibroid Embolization Agents Market Report Highlights

Aspects Details
By Type
  • Gelatin Sponge
  • Polyvinyl Alcohol (PVA) Particles
  • Trisacryl Gelatin Microspheres (TAGM)
  • Polymethyl Methacrylate (PMMA) Microspheres
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, UAE, Rest of LAMEA)
Key Market Players CeloNova, Biosciences, Nippon Kayaku, Astellas Pharma, Merit Medical Systems, Inc., Cook Medical, Boston Scientific Corporation, Pfizer
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: UTERINE FIBROID EMBOLIZATION AGENTS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Gelatin Sponge

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Polyvinyl Alcohol (PVA) Particles

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Trisacryl Gelatin Microspheres (TAGM)

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Polymethyl Methacrylate (PMMA) Microspheres

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: UTERINE FIBROID EMBOLIZATION AGENTS MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Type

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Uterine Fibroid Embolization Agents Market

        • 5.2.4.1. Market Size and Forecast, By Type

      • 5.2.5. Canada Uterine Fibroid Embolization Agents Market

        • 5.2.5.1. Market Size and Forecast, By Type

      • 5.2.6. Mexico Uterine Fibroid Embolization Agents Market

        • 5.2.6.1. Market Size and Forecast, By Type

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Type

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Uterine Fibroid Embolization Agents Market

        • 5.3.4.1. Market Size and Forecast, By Type

      • 5.3.5. Germany Uterine Fibroid Embolization Agents Market

        • 5.3.5.1. Market Size and Forecast, By Type

      • 5.3.6. Italy Uterine Fibroid Embolization Agents Market

        • 5.3.6.1. Market Size and Forecast, By Type

      • 5.3.7. Spain Uterine Fibroid Embolization Agents Market

        • 5.3.7.1. Market Size and Forecast, By Type

      • 5.3.8. UK Uterine Fibroid Embolization Agents Market

        • 5.3.8.1. Market Size and Forecast, By Type

      • 5.3.9. Russia Uterine Fibroid Embolization Agents Market

        • 5.3.9.1. Market Size and Forecast, By Type

      • 5.3.10. Rest Of Europe Uterine Fibroid Embolization Agents Market

        • 5.3.10.1. Market Size and Forecast, By Type

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Type

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Uterine Fibroid Embolization Agents Market

        • 5.4.4.1. Market Size and Forecast, By Type

      • 5.4.5. Japan Uterine Fibroid Embolization Agents Market

        • 5.4.5.1. Market Size and Forecast, By Type

      • 5.4.6. India Uterine Fibroid Embolization Agents Market

        • 5.4.6.1. Market Size and Forecast, By Type

      • 5.4.7. South Korea Uterine Fibroid Embolization Agents Market

        • 5.4.7.1. Market Size and Forecast, By Type

      • 5.4.8. Australia Uterine Fibroid Embolization Agents Market

        • 5.4.8.1. Market Size and Forecast, By Type

      • 5.4.9. Thailand Uterine Fibroid Embolization Agents Market

        • 5.4.9.1. Market Size and Forecast, By Type

      • 5.4.10. Malaysia Uterine Fibroid Embolization Agents Market

        • 5.4.10.1. Market Size and Forecast, By Type

      • 5.4.11. Indonesia Uterine Fibroid Embolization Agents Market

        • 5.4.11.1. Market Size and Forecast, By Type

      • 5.4.12. Rest of Asia Pacific Uterine Fibroid Embolization Agents Market

        • 5.4.12.1. Market Size and Forecast, By Type

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Type

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Uterine Fibroid Embolization Agents Market

        • 5.5.4.1. Market Size and Forecast, By Type

      • 5.5.5. South Africa Uterine Fibroid Embolization Agents Market

        • 5.5.5.1. Market Size and Forecast, By Type

      • 5.5.6. Saudi Arabia Uterine Fibroid Embolization Agents Market

        • 5.5.6.1. Market Size and Forecast, By Type

      • 5.5.7. UAE Uterine Fibroid Embolization Agents Market

        • 5.5.7.1. Market Size and Forecast, By Type

      • 5.5.8. Argentina Uterine Fibroid Embolization Agents Market

        • 5.5.8.1. Market Size and Forecast, By Type

      • 5.5.9. Rest of LAMEA Uterine Fibroid Embolization Agents Market

        • 5.5.9.1. Market Size and Forecast, By Type

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning,2022

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. Astellas Pharma

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Nippon Kayaku

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Pfizer

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. Boston Scientific Corporation

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. Merit Medical Systems, Inc.

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. Cook Medical

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. CeloNova

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Biosciences

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL UTERINE FIBROID EMBOLIZATION AGENTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL UTERINE FIBROID EMBOLIZATION AGENTS MARKET FOR GELATIN SPONGE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL UTERINE FIBROID EMBOLIZATION AGENTS MARKET FOR POLYVINYL ALCOHOL (PVA) PARTICLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL UTERINE FIBROID EMBOLIZATION AGENTS MARKET FOR TRISACRYL GELATIN MICROSPHERES (TAGM), BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL UTERINE FIBROID EMBOLIZATION AGENTS MARKET FOR POLYMETHYL METHACRYLATE (PMMA) MICROSPHERES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL UTERINE FIBROID EMBOLIZATION AGENTS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. NORTH AMERICA UTERINE FIBROID EMBOLIZATION AGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. NORTH AMERICA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 9. U.S. UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 10. CANADA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 11. MEXICO UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 12. EUROPE UTERINE FIBROID EMBOLIZATION AGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. EUROPE UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 14. FRANCE UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 15. GERMANY UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 16. ITALY UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. SPAIN UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. UK UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 19. RUSSIA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 20. REST OF EUROPE UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. ASIA-PACIFIC UTERINE FIBROID EMBOLIZATION AGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. ASIA-PACIFIC UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 23. CHINA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. JAPAN UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. INDIA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. SOUTH KOREA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. AUSTRALIA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. THAILAND UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. MALAYSIA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. INDONESIA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. REST OF ASIA PACIFIC UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. LAMEA UTERINE FIBROID EMBOLIZATION AGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 33. LAMEA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. BRAZIL UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. SOUTH AFRICA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. SAUDI ARABIA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. UAE UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 38. ARGENTINA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. REST OF LAMEA UTERINE FIBROID EMBOLIZATION AGENTS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. ASTELLAS PHARMA: KEY EXECUTIVES
  • TABLE 41. ASTELLAS PHARMA: COMPANY SNAPSHOT
  • TABLE 42. ASTELLAS PHARMA: OPERATING SEGMENTS
  • TABLE 43. ASTELLAS PHARMA: PRODUCT PORTFOLIO
  • TABLE 44. ASTELLAS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 45. NIPPON KAYAKU: KEY EXECUTIVES
  • TABLE 46. NIPPON KAYAKU: COMPANY SNAPSHOT
  • TABLE 47. NIPPON KAYAKU: OPERATING SEGMENTS
  • TABLE 48. NIPPON KAYAKU: PRODUCT PORTFOLIO
  • TABLE 49. NIPPON KAYAKU: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 50. PFIZER: KEY EXECUTIVES
  • TABLE 51. PFIZER: COMPANY SNAPSHOT
  • TABLE 52. PFIZER: OPERATING SEGMENTS
  • TABLE 53. PFIZER: PRODUCT PORTFOLIO
  • TABLE 54. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 55. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 56. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 57. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 58. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 59. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 60. MERIT MEDICAL SYSTEMS, INC.: KEY EXECUTIVES
  • TABLE 61. MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT
  • TABLE 62. MERIT MEDICAL SYSTEMS, INC.: OPERATING SEGMENTS
  • TABLE 63. MERIT MEDICAL SYSTEMS, INC.: PRODUCT PORTFOLIO
  • TABLE 64. MERIT MEDICAL SYSTEMS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 65. COOK MEDICAL: KEY EXECUTIVES
  • TABLE 66. COOK MEDICAL: COMPANY SNAPSHOT
  • TABLE 67. COOK MEDICAL: OPERATING SEGMENTS
  • TABLE 68. COOK MEDICAL: PRODUCT PORTFOLIO
  • TABLE 69. COOK MEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 70. CELONOVA: KEY EXECUTIVES
  • TABLE 71. CELONOVA: COMPANY SNAPSHOT
  • TABLE 72. CELONOVA: OPERATING SEGMENTS
  • TABLE 73. CELONOVA: PRODUCT PORTFOLIO
  • TABLE 74. CELONOVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. BIOSCIENCES: KEY EXECUTIVES
  • TABLE 76. BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 77. BIOSCIENCES: OPERATING SEGMENTS
  • TABLE 78. BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 79. BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL UTERINE FIBROID EMBOLIZATION AGENTS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL UTERINE FIBROID EMBOLIZATION AGENTS MARKET
  • FIGURE 3. SEGMENTATION UTERINE FIBROID EMBOLIZATION AGENTS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN UTERINE FIBROID EMBOLIZATION AGENTS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALUTERINE FIBROID EMBOLIZATION AGENTS MARKET
  • FIGURE 11. UTERINE FIBROID EMBOLIZATION AGENTS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. UTERINE FIBROID EMBOLIZATION AGENTS MARKET FOR GELATIN SPONGE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. UTERINE FIBROID EMBOLIZATION AGENTS MARKET FOR POLYVINYL ALCOHOL (PVA) PARTICLES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. UTERINE FIBROID EMBOLIZATION AGENTS MARKET FOR TRISACRYL GELATIN MICROSPHERES (TAGM), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. UTERINE FIBROID EMBOLIZATION AGENTS MARKET FOR POLYMETHYL METHACRYLATE (PMMA) MICROSPHERES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 17. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 18. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 19. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 20. COMPETITIVE DASHBOARD
  • FIGURE 21. COMPETITIVE HEATMAP: UTERINE FIBROID EMBOLIZATION AGENTS MARKET
  • FIGURE 22. Top player positioning, 2022
  • FIGURE 23. ASTELLAS PHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 24. ASTELLAS PHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 25. ASTELLAS PHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 26. NIPPON KAYAKU: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 27. NIPPON KAYAKU: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 28. NIPPON KAYAKU: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 29. PFIZER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. PFIZER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. PFIZER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. MERIT MEDICAL SYSTEMS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. MERIT MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. MERIT MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. COOK MEDICAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. COOK MEDICAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. COOK MEDICAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. CELONOVA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. CELONOVA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. CELONOVA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. BIOSCIENCES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. BIOSCIENCES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. BIOSCIENCES: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Uterine Fibroid Embolization Agents Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers